Merrimack expands Phase 3 NAPOLI-1 study
MM-398 is designed to optimise the delivery of irinotecan by extending the duration of circulation in the body and preferentially activating the drug within the tumour to achieve
ReviR Therapeutics has received a rare paediatric disease designation (RPDD) from the US Food and Drug Administration (FDA) for RTX-117, its investigational oral small-molecule therapy for Charcot-Marie-Tooth disease (CMT).
Voclosporin is a new generation calcineurin inhibitor licensed from Isotechnika Pharma. According to the approved protocol, the study will be a Phase III, randomized, multi-center, concentration-controlled comparison study